Acute lung injury associated with docetaxel and bevacizumab.
Prat
A
A
Martínez
P
P
Serrano
C
C
Montero
M A
MA
Andreu
J
J
Cortés
J
J
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000188:drug therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D043823:Taxoids / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D000068258:Bevacizumab